Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CERE-120: AAV2-NTN · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CERE-120: AAV2-NTN | GENETIC | - |
Inclusion Criteria: * Diagnosis of bilateral idiopathic Parkinson's Disease of at least 5 years duration since diagnosis with motor fluctuations, despite adequate oral antiparkinsonian therapy. * Diagnosis of moderate to severe Parkinson's Disease based on clinical rating scales. * Males or nonpreg...
Top 15 of 24 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biohaven Ltd. | BHVN | 1 | PHASE3 | BHV-8000 |
| Eli Lilly and Company | LLY | 4 | PHASE2 | LY3884961, LY4006896, LY3962681 |
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Annovis Bio Inc | ANVS | 1 | PHASE3 | Buntanetap |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE2 | AAV-GAD |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | RO7568282 |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Aspen Neuroscience | ASPE | 1 | PHASE1 | ANPD001 |
CERE-120 is an investigational gene therapy developed for idiopathic Parkinson's disease. It was studied in a Phase 1 safety trial in the United States enrolling 12 participants aged 35 years and older. It is a gene therapy candidate rather than an approved treatment for Parkinson's disease.
CERE-120 is being developed by Sangamo Therapeutics, Inc., which trades under the ticker SGMOQ. The company is the sponsor associated with the CERE-120 gene therapy program for Parkinson's disease.
CERE-120 is in Phase 1 clinical development. Its single recorded trial, NCT00252850, is a completed Phase 1 study evaluating safety in subjects with idiopathic Parkinson's disease. CERE-120 is investigational and is not an approved therapy.
CERE-120 has been studied in trial NCT00252850, titled Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease. It was a completed Phase 1 study conducted in the United States with 12 enrolled participants, open to all sexes aged 35 years and older, and it did not include healthy volunteers.
No. The Phase 1 trial of CERE-120, NCT00252850, was an uncontrolled study with no randomization and no double blinding. It enrolled 12 participants with idiopathic Parkinson's disease and was designed to assess safety rather than to compare CERE-120 against a placebo or active comparator.
Yes. CERE-120 and AAV2-NTN refer to the same investigational gene therapy candidate. CERE-120 is the program name used by Sangamo Therapeutics, Inc., while AAV2-NTN appears in the title of its Phase 1 Parkinson's disease trial, NCT00252850.